Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Switzerland-based Basilea Pharmaceutica has announced that Toctino, a new once-daily oral treatment for adults with severe chronic hand eczema unresponsive to potent topical corticosteroids, has been approved by the Medicines and Healthcare products Regulatory Agency in the UK.
Subscribe to our email newsletter
Following the recommendation for regulatory approval under the European decentralized procedure, Toctino received its first national regulatory approval in the UK.
Marketing applications for the use of alitretinoin in the treatment of severe chronic refractory hand eczema are also under regulatory review in Canada and in Switzerland.